Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Seroma × Clear all

Phase

Phase NA 22 Phase 4 6 Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2319 Carcinoma, Non-Small-Cell Lung 1882 Prostatic Neoplasms 1220 Colorectal Neoplasms 1074 Neoplasms 1040 Multiple Myeloma 905 Lung Neoplasms 865 Neoplasm Metastasis 842 Leukemia, Myeloid, Acute 821 Lymphoma 750 Melanoma 732 Pancreatic Neoplasms 694 Ovarian Neoplasms 673 Carcinoma, Hepatocellular 645 Recurrence 642 Stomach Neoplasms 633 Leukemia 627 Lymphoma, Non-Hodgkin 570 Leukemia, Lymphocytic, Chronic, B-Cell 552 Lymphoma, Large B-Cell, Diffuse 523 Squamous Cell Carcinoma of Head and Neck 518 Precursor Cell Lymphoblastic Leukemia-Lymphoma 502 Brain Neoplasms 502 Head and Neck Neoplasms 501 Glioblastoma 494 Carcinoma, Renal Cell 483 Rectal Neoplasms 480 Myelodysplastic Syndromes 442 Sarcoma 431 Lymphoma, Follicular 430

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02668588 2017-02-02

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Chemi S.p.A.

Phase 2 Completed

Seroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡